Groowe Groowe / Newsroom / DNLI
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

DNLI News

Denali Therapeutics Inc. Common Stock

Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)

prnewswire.com
DNLI

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

globenewswire.com
SRPT ALNY DNLI ARCT

Courier Health Releases 2026 State of Patient-Centricity in Biopharma Report

prnewswire.com
AZN DNLI GNE PFE UCB

Form 8-K

sec.gov
DNLI

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

globenewswire.com
DNLI

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

prnewswire.com
PRME IOVA MDGL DNLI

Form 8-K

sec.gov
DNLI

Form 8-K

sec.gov
DNLI

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

globenewswire.com
DNLI

Advanced Cell-based Therapy Booming the Success for Healthcare Sector

prnewswire.com
PRME IOVA MDGL DNLI